Positive Results Published for D-Pharm's Drug Discovery Program in Alzheimer's and Stroke

24-Mar-2004

Rehovot, Israel. D-Pharm Ltd. announced that its exciting results with DP-109 in an in vivo transgenic mouse model for Alzheimer's disease are now available online in Neurobiology of Aging. This study clearly demonstrates effect of the lipophilic metal ion modulator DP-109 on reducing amyloid pathology in the brains of human beta-amyloid precursor protein transgenic mice.

Daily oral administration of DP-109 for 3 months markedly reduced the burden of amyloid plaques and the degree of cerebral amyloid angiopathy (CAA) in brains, compared to animals receiving vehicle treatment. Moreover, DP-109 treatment facilitated the transition of amyloid-beta from insoluble to soluble forms and moderation of brain inflammation characteristic of AD. DP-109 is the second compound to emerge from D-Pharm's metal ion modulator based drug discovery program and is a lead candidate for combating neurodegenerative disease.

Earlier this year, results from a Phase II Acute Stroke Study with D-Pharm's most advanced metal ion modulator, DP-b99, were published in Stroke (2004). This Phase II study was performed as a randomized, double-blind, placebo-controlled trial. The purpose of the study was to determine whether DP-b99 could be safely used in patients within a 12-hour time window following a stroke incident and to provide important pharmacokinetics and dosing information for future pivotal efficacy trials. Analysis of the data indicates that DP-b99 may be safely administered in this patient population. Rates of mortality, serious adverse events and overall adverse events were not higher in the DP-b99 group compared to placebo and no major side effects were attributed to the treatment. Efficacy evaluation demonstrates improvements in the clinical neurological scale score (NIHSS) 2, 7 and 30 days after the stroke in drug-treated patients.

Two-lock box delivers cancer therapy

Read news

About the technology

Disrupted metal ion homeostasis is symptomatic of numerous diseases, ranging from inflammation, cardiac arrhythmia, myocardial infarction and acute stroke to chronic neuro-degeneration (e.g. Alzheimer's and Parkinson's diseases). D-Pharm's breakthrough was to recognize metal ion distribution within cell membranes as a distinct, novel target for therapeutic intervention.

D-Pharm's platform technology enables rational design of lipophilic drugs to modulate the distribution of metal ions such as copper, zinc, calcium and iron selectively within cell membranes and membrane milieus, rendering their action localized and safe. The resulting drug candidates are unique in that they operate at a number of selected targets critically involved in the disease process, providing a broad base for therapeutic effect. Our distinctive ability to modulate metal ion distribution selectively within the membrane offers a unique opportunity for powerful yet safe therapeutics in many human disorders.

About Alzheimer's disease and stroke

Currently more than 2% of the population aged 55 and over in developed countries (the United States, Western Europe and Japan) is affected by Alzheimer's disease. Growth in the number of elderly in these markets is expected to increase the total prevalence to greater than 10 million within the next 5 years. No effective treatment is available to prevent or reverse the deterioration that results from Alzheimer's disease. With no truly neuroprotective drugs on the market, there is a huge unmet need for new therapies.

Stroke is one of the world's most prevalent pathologies, rated as the third leading cause of death and second leading cause of neurological morbidity in the US, Europe, and Japan. After a stroke victim arrives at the hospital emergency room, clinicians must diagnose and initiate treatment within a six-hour window, during the medical crisis.

https://www.bionity.com/en/news/36253/positive-results-published-for-d-pharm-s-drug-discovery-program-in-alzheimer-s-and-stroke.html